|
ESF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.02899968732618E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.36889999838397E-08 |
| Normal-vs-Stage2 |
5.20169999962405E-07 |
| Normal-vs-Stage3 |
1.28840000002128E-06 |
| Normal-vs-Stage4 |
1.74540000008605E-07 |
| Stage1-vs-Stage2 |
2.787000E-01 |
| Stage1-vs-Stage3 |
8.154600E-01 |
| Stage1-vs-Stage4 |
1.716220E-01 |
| Stage2-vs-Stage3 |
4.327600E-01 |
| Stage2-vs-Stage4 |
8.293800E-01 |
| Stage3-vs-Stage4 |
3.073000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.00020000060042E-08 |
| Normal-vs-AfricanAmerican |
2.681100E-03 |
| Normal-vs-Asian |
7.74470000000083E-05 |
| Caucasian-vs-AfricanAmerican |
6.810600E-01 |
| Caucasian-vs-Asian |
9.677600E-01 |
| AfricanAmerican-vs-Asian |
7.152600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.18209997346241E-09 |
| Normal-vs-Female |
8.02220000428733E-08 |
| Male-vs-Female |
5.975900E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.36049999999166E-06 |
| Normal-vs-Age(41-60Yrs) |
2.13700002138495E-09 |
| Normal-vs-Age(61-80Yrs) |
1.71429999973327E-07 |
| Normal-vs-Age(81-100Yrs) |
2.720700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.224600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.183800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.239200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.607000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.075600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.292200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.257000E-01 |
| Classical-VS-Follicular |
1.415340E-03 |
| Classical-VS-Other |
3.618400E-01 |
| Classical-VS-Normal |
2.873600000175E-07 |
| Tall-VS-Follicular |
9.265500E-02 |
| Tall-VS-Other |
4.128000E-01 |
| Tall-VS-Normal |
7.021600E-04 |
| Follicular-VS-Other |
8.771000E-01 |
| Follicular-VS-Normal |
1.81299997237261E-09 |
| Other-VS-Normal |
1.090060E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.20690013538649E-10 |
| Normal-vs-N1 |
1.193330E-04 |
| N0-vs-N1 |
2.898600E-01 |
|
|
